Macrocure announces new date for Special General Meeting of Shareholders
Macrocure announced that it has delayed the scheduled date for its previously-announced Special General Meeting of Shareholders by one week, to Monday, December 19, 2016, at 3:00 p.m., Israel time (8:00 a.m. EST). The special meeting will be held at the offices of Macrocure's Israeli counsel, Meitar Liquornik Geva Leshem Tal, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. At the special meeting, the company's prospective merger with Leap Therapeutics, a clinical stage immuno-oncology company, will be presented for approval. As previously announced, pursuant to the prospective merger, Macrocure will become a wholly owned subsidiary of Leap, and Leap will become a public company. In connection with the transaction, Leap is applying to have the shares of the combined entity listed for trading on NASDAQ upon completion of the merger, the approval of such application being a condition to the consummation of the merger. Macrocure has delayed the meeting date in order to provide more time for its shareholders to receive and review the proxy materials for the meeting, and to vote via the proxy card included in that mailing. The proxy materials are now in the process of being mailed, given that the review process of the SEC, with respect to the Leap prospectus, is now completed and the Leap registration statement on Form S-4, of which that prospectus forms a part, has been declared effective. The record date for determining shareholders entitled to vote at the meeting remains Friday, November 11, 2016.